Wockhardt Returns to Profit in FY26 Amid US Generics Exit and Rising Debt

Consolidated net profit stood at ₹199 crore for FY26, a significant turnaround from a loss of ₹57 crore last year. Standalone revenue grew a robust 28.76% year-over-year to ₹1,876 crore.

Financial Highlights for FY26

Wockhardt Ltd has posted a consolidated net profit of ₹199 crore for the fiscal year ended March 31, 2026. The company’s consolidated total income grew to ₹3,484 crore.

On a standalone basis, Wockhardt reported a net profit of ₹317 crore for FY26, a significant improvement from a net loss of ₹12 crore in FY25. Standalone total income rose by 28.76% year-over-year to ₹1,876 crore.

For the fourth quarter ended March 31, 2026, consolidated net profit was ₹164 crore on total income of ₹1,010 crore. Standalone net profit for the quarter was ₹167 crore on total income of ₹571 crore.

A one-time gain of ₹35 crore from a legal settlement with Dr. Reddy's Laboratories contributed positively to the latest quarterly results.

Strategic Shift and Key Challenges

The company's return to profitability follows a period of losses, driven by revenue growth and specific gains. This turnaround signals a move towards stronger financial health. However, exiting the US generics market and increasing long-term debt bring new challenges.

These results underscore Wockhardt's strategic pivot. The company aims to divest underperforming operations to concentrate on high-growth areas such as novel antibiotics and biologics.

Impact on Operations and Strategy

• Shareholders benefit from a return to profitability at both standalone and consolidated levels.
• The company's focus sharpens on its R&D pipeline for novel antibiotics and biologics, aiming for higher-margin products.
• Divesting loss-making US operations is expected to improve overall profitability.
• Investors will monitor how effectively the company replaces revenue from the exited US generics business.

Key Risks to Monitor

• US Business Exit: The voluntary liquidation of subsidiaries Morton Grove Pharmaceuticals Inc. and Wockhardt USA LLC incurred an ₹85 crore exceptional charge. This exit affects the company's geographic presence and revenue.
• Rising Debt: Consolidated long-term borrowings rose to ₹1,518 crore (FY26) from ₹1,211 crore (FY25), showing increased leverage.
• Operational Margin Gap: Wockhardt's operating profit margin (OPM) was 13.1% in FY25, well below the industry average of 24-25%, highlighting a need for better cost efficiency.

Peer Comparison

Major Indian pharmaceutical players like Sun Pharma and Dr. Reddy's Laboratories have shown consistent revenue growth and profitability. While the Indian pharma industry's operating profit margins are projected to remain stable at 24-25% in FY2026, Wockhardt’s standalone OPM stood at approximately 13.1% in FY25, highlighting a performance gap that needs to be addressed through operational improvements and a strategic focus on higher-margin products.

Key Financial Metrics

• Consolidated total income: ₹3,484 crore (FY26), up 13.34% from ₹3,074 crore (FY25).
• Standalone total income: ₹1,876 crore (FY26), up 28.76% from ₹1,457 crore (FY25).
• Consolidated long-term borrowings: ₹1,518 crore (March 31, 2026), up from ₹1,211 crore (March 31, 2025).

Outlook and Future Focus

• Future revenue growth and profitability after exiting US generics.
• Strategy for managing and reducing long-term debt.
• Performance of the innovation pipeline for novel antibiotics and biologics.
• Progress in improving operating margins towards industry benchmarks.
• Further strategic moves or divestments.